AR069461A1 - Uso de melanocortinas para tratar la sensibilidad a insulina - Google Patents

Uso de melanocortinas para tratar la sensibilidad a insulina

Info

Publication number
AR069461A1
AR069461A1 ARP080104846A ARP080104846A AR069461A1 AR 069461 A1 AR069461 A1 AR 069461A1 AR P080104846 A ARP080104846 A AR P080104846A AR P080104846 A ARP080104846 A AR P080104846A AR 069461 A1 AR069461 A1 AR 069461A1
Authority
AR
Argentina
Prior art keywords
cys
arg
phe
seq
trp
Prior art date
Application number
ARP080104846A
Other languages
English (en)
Original Assignee
Univ Louisiana State
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State, Sod Conseils Rech Applic filed Critical Univ Louisiana State
Publication of AR069461A1 publication Critical patent/AR069461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a ligandos péptidos de los receptores de melanocortina, en particular, el receptor de melanocortina 4, y como tales, son utiles en el tratamiento de trastornos sensibles a la activacion de este receptor, tales como la resistencia a la insulina. Reivindicacion 1: Uso de un agonista del receptor de melanocortina 4 caracterizado porque es para la manufactura de un medicamento util para el tratamiento de la resistencia a la insulina en un sujeto que lo necesita. Reivindicacion 2: El uso de acuerdo con la reivindicacion 1, donde dicho agonista de receptor de melanocortina 4 util para el tratamiento de la resistencia a la insulina se selecciona del grupo que consiste en: Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-b-Ala-Lys)-NH2, SEQ. ID. Ns 1; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2, SEQ. ID. NRO,: 1; Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2, SEQ. ID. Ns 2; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2, SEQ. ID. Ns 3; D-Phe-c(Cys-His-D-Phe-Arg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 3; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2, SEQ. ID. Ns 3; Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2, SEQ. ID. Ns 2; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2, SEQ. ID. Ns 4; Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 5; Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 6; Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 6; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 6; Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-Nle-c(Cys-b-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-NIe-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-NIe-c(Cys-GIy-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 7; Ac-NIe-c(D-Cys-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-b-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(D-Cys-GIy-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 8; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-b-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(Cys-GIy-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 9; Ac-NIe-c(D-Cys-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-D-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-b-AIa-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-NIe-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2, SEQ. ID. Ns 10; Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEC. ID. Ns 11; Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; n-butanoiI-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2 SEQ. ID. Ns 12; Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-b-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 11; Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEC. ID. Ns 13; Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 13; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-D-AIa-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-b-AIa-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2, SEQ. ID. Ns 14; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-b-AIa-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-D-AIa-Cys)-NH2, SEQ. ID. Ns 15; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 16; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-2-NaI-Cys)-NH2, SEQ. ID. Ns 16; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-1-NaI-Cys)-NH2, SEQ. ID. Ns 16; n-butanoil-NIe-c(Cys-D-AIa-His-D-Phe-Arg-2-NaI-Cys)-NH2, SEQ. ID. Ns 17; n-butanoil-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 17; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-2-NaI-Cys)-NH2, SEQ. ID. Ns 18; Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-NaI-Cys)-NH2, SEQ. ID. Ns 18; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-BaI-Cys)-NH2, SEQ. ID. Ns 18; Ac-NIe-c(Cys-D-GIu-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 59; Ac-NIe-c(Asp-His-D-Phe-Arg-Trp-D-AIa-LYS)-NH2, SEQ. ID. Ns 19; Ac-NIe-c(Cys-D-AIa-Hs-D-2-NaI-Arg-BaI-Cys)-NH2, SEQ. ID. Ns 20; Ac-NIe-c(Pen-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 21; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 22; Ac-NIe-c(Pen-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 22; D-Phe-c(Cys-His-D-Phe-hArg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 23; D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 24; D-Phe-c(Cys-His-D-Phe-Arg-Bip-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 25; D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 24; D-Phe-c(Cys-His-D-Phe-hArg-Bip-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 26; D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-b-AIa-D-Cys)-Thr-NH2, SEQ. ID. Ns 26; NIe-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2, SEQ. ID. Ns 27; Ac-NIe-c(Asp-D-AIa-His-D-Phe-Arg-Trp-Lys)-NH2, SEQ. ID. Ns 28; Ac-NIe-c(Asp-D-AIa-His-D-Phe-Arg-BaI-Lys)-NH2, SEQ. ID. Ns 28; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-OH, SEQ. ID. Ns 29; Ac-NIe-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-VaI-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID, Ns 30; Ac-NIe-c(Cys-D-IIe-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-TIe-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 30; Ac-NIe-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 31; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 32; Ac-NIe-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 32; Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-IIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEC. ID. Ns 33; Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-VaI-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; Ac-2-NaI-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 33; NIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 34; Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 34; Ac-NIe-c(Cys-3-PaI-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 35; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-OH SEQ. ID. Ns 36; Ac-NIe-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 37; Ac-NIe-c(Asp-His-D-2-NaI-Arg-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 38; Ac-Nle-c(Asp-Hs-D-2-NaI-Arg-Trp-b-AIa-Lys)-NH2, SEQ, ID. Ns 38; Ac-NIe-c(Cys-His-D-2-NaI-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 39; Ac-NIe-c(Cys-His-D-2-NaI-Arg-Trp-Ahx-Cys)-NH2, SEQ. ID. Ns 39; Ac-hPhe-c(Asp-His-D-2-NaI-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 40; Ac-Cha-c(Asp-His-D-2-NaI-Arg-Trp-Gaba-Lys)-NH2, SEQ. ID. Ns 40; Ac-NIe-c(Asp-Hs-D-Phe-Arg-Trp-b-AIa-Lys)-OH SEQ. ID. Ns 41; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH SEQ. ID. Ns 42; D-Phe-c(Cys-His-D-Phe-Arg-Trp-AIa-D-Cys)-Thr-OH SEQ. ID. Ns 43; D-Phe-c(Cys-His-D-Phe-Arg-Trp-b-AIa-D-Cys)-Thr-OH SEQ. ID. Ns 43; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-thr-OH SEQ. ID. Ns 43; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH SEQ. ID. Ns 42; Ac-NIe-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH SEQ. ID. Ns 41; Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH SEQ. ID. Ns 44; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-b-AIa-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-His-D-Phe-Arg-D-Trp-D-AIa-Cys)-OH SEQ. ID. Ns 45; Ac-NIe-c(Cys-D-Ala-His-D-2-NaI-Arg-Trp-Cys)-OH SEQ. ID. Ns 46; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-2-NaI-Cys)-OH SEC. ID. Ns 46; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-1-NaI-Cys)-OH SEQ. ID. Ns 46; Ac-NIe-c(Cys-D-AIa-His-D-2-NaI-Arg-BaI-Cys)-OH SEQ. ID. Ns 46; Ac-NIe-c(Pen-D-AIa-His-D-Phe-Arg-Trp-Cys)-OH SEQ. ID. Ns 47; Ac-NIe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH SEQ. ID. Ns 48; Ac-Arg-c(Cys-D-AIa-His-D-2-NaI-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 49; Ac-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 50; Ac-D-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Cys)-NH2, SEQ. ID. Ns 50; Ac-D-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 51; Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 52; Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, SEQ. ID. Ns 52; Ac-Arg-c(Cys-D-AIa-His-D-Phe-Arg-Trp-Pen)-NH2, SEQ. ID. Ns 51; Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 53; Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-AIa-Lys)-NH2, SEQ. ID. Ns 53; Ac-NIe-c(Cys-3-PaI-D-Phe-Arg-Trp-Gaba-Cys)-NH2, SEQ. ID. Ns 35; Ac-NIe-c(Cys-D-AIa-His-D-Phe-Arg-Trp-GIy-Cys)-NH2, SEQ. ID. N
ARP080104846A 2007-11-05 2008-11-05 Uso de melanocortinas para tratar la sensibilidad a insulina AR069461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US193307P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
AR069461A1 true AR069461A1 (es) 2010-01-27

Family

ID=40626385

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104846A AR069461A1 (es) 2007-11-05 2008-11-05 Uso de melanocortinas para tratar la sensibilidad a insulina

Country Status (21)

Country Link
US (6) US9155777B2 (es)
EP (2) EP2979703B1 (es)
JP (3) JP2011502987A (es)
KR (3) KR20150013339A (es)
CN (2) CN101980717A (es)
AR (1) AR069461A1 (es)
AU (1) AU2008325194B2 (es)
BR (1) BRPI0819188B1 (es)
CA (2) CA2952095C (es)
DK (1) DK2214693T3 (es)
ES (2) ES2690556T3 (es)
HK (3) HK1146242A1 (es)
HU (1) HUE026842T2 (es)
IL (2) IL205554A (es)
NZ (1) NZ585131A (es)
PL (1) PL2214693T3 (es)
PT (2) PT2979703T (es)
RU (1) RU2453328C2 (es)
TR (1) TR201815292T4 (es)
TW (1) TWI374030B (es)
WO (1) WO2009061411A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2689016C (en) * 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
RU2012108110A (ru) * 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии
HUE031856T2 (en) * 2009-08-31 2017-08-28 Tensive Controls Inc Stabilized melanocortin ligands
RU2548753C2 (ru) 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
EP2504351A4 (en) 2009-11-23 2013-10-30 Palatin Technologies Inc MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE
MX2012005862A (es) 2009-11-23 2012-09-07 Palatin Technologies Inc Peptidos ciclicos especificos del receptor de melanocortina-1.
WO2012172433A2 (en) * 2011-06-14 2012-12-20 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
RU2019116003A (ru) 2013-03-15 2019-07-17 Ритм Фармасьютикалз, Инк. Фармацевтические композиции
CN118240012A (zh) 2013-03-15 2024-06-25 节奏制药公司 肽组合物
US10314883B2 (en) 2015-02-13 2019-06-11 University Of Virginia Patent Foundation Compositions and methods for regulating blood pressure
WO2017019952A1 (en) 2015-07-29 2017-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating leukocyte adhesion
WO2017049140A2 (en) 2015-09-18 2017-03-23 Wake Forest University Health Sciences Angiotensin (1-7) analogs and methods relating thereto
US11124541B2 (en) * 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CA3102603A1 (en) 2018-06-05 2019-12-12 The Research Foundation For The State University Of New York Method for passive wireless channel estimation in radio frequency network and apparatus for same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
US7034033B2 (en) * 2002-05-23 2006-04-25 Chiron Corporation Substituted quinazolinone compounds
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
JP2006521359A (ja) 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン−４受容体作働薬としての二環式ピペリジン誘導体
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
US20070123453A1 (en) * 2004-03-29 2007-05-31 Heiman Mark L Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion
WO2006049933A2 (en) * 2004-10-29 2006-05-11 Merck & Co., Inc. Compositions and methods for the treatment of obesity and sexual dysfunction
WO2007008684A2 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands of melanocortin receptors
KR101232201B1 (ko) * 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
CA2689016C (en) * 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) * 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
RU2453328C2 (ru) * 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
RU2012108110A (ru) 2009-08-05 2013-09-10 Ипсен Фарма С.А.С. Применение меланокортинов для лечения дислипидемии

Also Published As

Publication number Publication date
JP5964767B2 (ja) 2016-08-03
IL205554A0 (en) 2010-12-30
CN103316345B (zh) 2016-05-18
EP2214693B1 (en) 2015-09-09
KR101662044B1 (ko) 2016-10-04
KR20100075680A (ko) 2010-07-02
HUE026842T2 (en) 2016-08-29
EP2979703A1 (en) 2016-02-03
PL2214693T3 (pl) 2016-03-31
WO2009061411A2 (en) 2009-05-14
ES2690556T3 (es) 2018-11-21
CA2952095C (en) 2020-02-18
US20220339239A1 (en) 2022-10-27
NZ585131A (en) 2012-10-26
JP2015131827A (ja) 2015-07-23
JP2011502987A (ja) 2011-01-27
US9155777B2 (en) 2015-10-13
EP2214693A4 (en) 2012-04-11
IL205554A (en) 2017-01-31
US9827286B2 (en) 2017-11-28
TW200932258A (en) 2009-08-01
US9439943B2 (en) 2016-09-13
WO2009061411A3 (en) 2010-04-15
KR20150013339A (ko) 2015-02-04
US20190111105A1 (en) 2019-04-18
EP2979703B1 (en) 2018-07-18
EP2214693A2 (en) 2010-08-11
TWI374030B (en) 2012-10-11
PT2214693E (pt) 2015-12-07
US20180303899A1 (en) 2018-10-25
US20150366934A1 (en) 2015-12-24
BRPI0819188B1 (pt) 2021-06-22
DK2214693T3 (en) 2015-11-30
JP2013144690A (ja) 2013-07-25
KR20130065725A (ko) 2013-06-19
IL249998A0 (en) 2017-03-30
AU2008325194A1 (en) 2009-05-14
CN101980717A (zh) 2011-02-23
RU2010122897A (ru) 2011-12-20
PT2979703T (pt) 2018-10-31
TR201815292T4 (tr) 2018-11-21
KR101290623B1 (ko) 2013-08-07
HK1184692A1 (zh) 2014-01-30
ES2555522T3 (es) 2016-01-04
US20160354429A1 (en) 2016-12-08
CN103316345A (zh) 2013-09-25
BRPI0819188A2 (pt) 2015-09-01
CA2952095A1 (en) 2009-05-14
US20100311647A1 (en) 2010-12-09
CA2704651A1 (en) 2009-05-14
HK1221147A1 (zh) 2017-05-26
CA2704651C (en) 2017-03-07
AU2008325194B2 (en) 2012-04-19
IL249998B (en) 2018-07-31
HK1146242A1 (en) 2011-05-27
RU2453328C2 (ru) 2012-06-20

Similar Documents

Publication Publication Date Title
AR069461A1 (es) Uso de melanocortinas para tratar la sensibilidad a insulina
AR063279A1 (es) Ligandos del receptor de melanocortina modificados con hidantoina
Sharp Multiple opioid receptors on immune cells modulate intracellular signaling
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
Illes Modulation of transmitter and hormone release by multiple neuronal opioid receptors
PE20210162A1 (es) Analogos de incretina y sus usos
PE20141178A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
PE20200675A1 (es) Peptido activador de receptor de gip
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
AR064032A1 (es) Usos terapeuticos de polipeptidos heterologos il-17a/f
EA201290027A1 (ru) Ацилированные аналоги глюкагона
DOP2010000294A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CL2011003095A1 (es) Peptido ciclico especifico para receptores de melanocortina; uso para tratar diabetes, obesidad, sobrepeso y/o enfermedades, transtornos y/o afecciones asociadas con la obesidad y/o sobrepeso, incluyendo resistencia a la insulina.
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
UY31877A (es) Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669
ATE519498T1 (de) Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
Kimura et al. Intradermal application of nociceptin increases vascular permeability in rats: the possible involvement of histamine release from mast cells
Jimenez-Andrade et al. Activation of peripheral galanin receptors: differential effects on nociception
ES2723098T3 (es) Agonistas del péptido CRHR2 y usos de los mismos
Quillet et al. Identification of an N-acylated-DArg-Leu-NH2 dipeptide as a highly selective neuropeptide FF1 receptor antagonist that potently prevents opioid-induced hyperalgesia
Lengyel et al. A novel non-opioid binding site for endomorphin-1
Sandrini et al. Nociceptin/orphanin FQ prevents the antinociceptive action of paracetamol on the rat hot plate test

Legal Events

Date Code Title Description
FB Suspension of granting procedure